News|Articles|October 3, 2016

Baxter Recalls Micron Filters

The company is voluntarily recalling all unexpired lots of 50-mm, 0.2-micron filters.

Baxter announced on Sept. 27, 2016 that it was voluntarily recalling all unexpired lots of 50-mm, 0.2-micron filters because of the potential for a missing filter support membrane and the potential presence of particulate matter. The component was manufactured by an external supplier, and the problems were identified by compounding pharmacies before the product reached patients.

The recalled filters, which filter bacteria and particulates, are used for aqueous solutions during compounding. According to Baxter, “In the absence of the filter support membrane, bacteria and/or particulate matter present in an unsterile solution could pass through to the compounded prepared solution. If not further filtered before patient administration, this could lead to adverse health consequences.”

The recalled lots were distributed between August 22, 2013 and June 20, 2016. The recalled product code is H93835, with an expiration date of June 27, 2016–June 27, 2019.

Source: FDA


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.